US regulators are bringing into force labelling changes for Merck Serono’s and Genentech’s psoriasis drug Raptiva (efalizumab) after post-marketing studies have highlighted increased risk of serious infections.
Read MoreThe European Commission is expected to put forward a proposal later this month that will give the European Medicines Agency the power to require specific product identification in a bid to stop counterfeit drugs.
Read MoreEli Lilly and partner Daiichi Sankyo have been forced to release a statement reassuring investors their blood-thinner prasugrel will continue to move through the approval process amid media speculation US regulators are again delaying a decision.
Read MoreCell Genesys is slashing three-quarters of its workforce after announcing it is terminating its VITAL-1 Phase III clinical trial of its prostate cancer immunotherapy agent GVAX and is halting further development of the drug.
Read MoreGenentech’s strong third-quarter results have led to analyst predictions that Roche will increase its bid to buy up the biotech company.
Read More
